Literature DB >> 12511746

Inherited thrombophilic disorders in young adults with ischemic stroke and patent foramen ovale.

Alessandro Pezzini1, Elisabetta Del Zotto, Mauro Magoni, Angelo Costa, Silvana Archetti, Mario Grassi, Nabil Maalikjy Akkawi, Alberto Albertini, Deodato Assanelli, Luigi Amedeo Vignolo, Alessandro Padovani.   

Abstract

BACKGROUND AND
PURPOSE: The pathogenic link between patent foramen ovale (PFO) and stroke remains unknown in most cases. We investigated the association between inherited thrombophilic disorders and PFO-related strokes in a series of young adults in the setting of a case-control study.
METHODS: We investigated 125 consecutive subjects (age, 34.7+/-7.3 years) with ischemic stroke and 149 age- and sex-matched control subjects. PFO was assessed in all patients with transcranial Doppler sonography with intravenous injection of agitated saline according to a standardized protocol. Genetic analyses for the factor V (FV)(G1691A) mutation, the prothrombin (PT)(G20210A) variant, and the TT677 genotype of methylenetetrahydrofolate reductase (MTHFR) were performed in all subjects.
RESULTS: A pathogenic role of PFO was presumed in 36 patients (PFO+). Interatrial right-to-left shunt either was not detected or was considered unrelated to stroke occurrence in the remaining 89 patients (PFO-). The PT(G20210A) variant was more frequent in the PFO+ group compared with control subjects and the PFO- group (PFO+ versus control subjects, 11% versus 2%; 95% CI, 0.04 to 0.94; PFO+ versus PFO-, 11% versus 1.1%; 95% CI, 1.09 to 109; P=0.047). A similar distribution was observed for subjects carrying either the PT(G20210A) variant or the FV(G1691A) mutation (PFO+ versus control subjects, 19.4% versus 5.3%; 95% CI, 0.08 to 0.75; PFO+ versus PFO-, 19.4% versus 3.3%; 95% CI, 1.45 to 26.1; P=0.021). Combined thrombophilic defects were observed in 3 subjects of the PFO+ group, in 2 control subjects (8.3% versus 1.3%; 95% CI, 0.01 to 0.66; P=0.015), and in 0 subjects in the PFO- group. A trend toward a difference in the frequency of the FV(G1691A) mutation between PFO+ and control subjects was found after bivariate analysis (11% versus 3.3%; P=0.068) but not after multinomial logistic regression analysis. No significant association was found in the distribution of the TT MTHFR genotype in the 3 groups.
CONCLUSIONS: In young adults, the PT(G20210A) variant and, to a lesser extent, the FV(G1691A) mutation may represent risk factors for PFO-related cerebral infarcts. A role of systemic thrombophilic disorders in the pathogenesis of this specific subtype of stroke may be hypothesized.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12511746     DOI: 10.1161/01.str.0000046457.54037.cc

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  33 in total

1.  Interaction of homocysteine and conventional predisposing factors on risk of ischaemic stroke in young people: consistency in phenotype-disease analysis and genotype-disease analysis.

Authors:  A Pezzini; M Grassi; E Del Zotto; D Assanelli; S Archetti; R Negrini; L Caimi; A Padovani
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-04-19       Impact factor: 10.154

2.  Thrombophilias and stroke: diagnosis, treatment, and prognosis.

Authors:  Madeline C Fields; Steven R Levine
Journal:  J Thromb Thrombolysis       Date:  2005-10       Impact factor: 2.300

Review 3.  Causes of death among persons who survive an acute ischemic stroke.

Authors:  Shuai Zhang; Wen-Bin He; Nai-Hong Chen
Journal:  Curr Neurol Neurosci Rep       Date:  2014-08       Impact factor: 5.081

4.  Patent foramen ovale and stroke: prognosis and treatment in young adults.

Authors:  Steven C Cramer
Journal:  J Thromb Thrombolysis       Date:  2005-10       Impact factor: 2.300

5.  [Cardiac workup after cerebral ischemia. Consensus paper of the Working Group on Heart and Brain of the German Cardiac Society and German Stroke Society].

Authors:  U Laufs; U C Hoppe; S Rosenkranz; P Kirchhof; M Böhm; H-C Diener; M Endres; M Grond; W Hacke; T Meinertz; E B Ringelstein; J Röther; M Dichgans
Journal:  Nervenarzt       Date:  2010-04       Impact factor: 1.214

Review 6.  Patent foramen ovale and stroke.

Authors:  Shunichi Homma; Marco R Di Tullio
Journal:  J Cardiol       Date:  2010-06-29       Impact factor: 3.159

7.  Can interaction between atrial septal abnormalities and genetic prothrombotic polymorphisms play a role in cryptogenic ischemic stroke? Description of a family.

Authors:  Rocco Salvatore Calabrò; Giuseppe Gervasi; Placido Bramanti
Journal:  Neurol Sci       Date:  2011-05-26       Impact factor: 3.307

Review 8.  The brain's heart - therapeutic opportunities for patent foramen ovale (PFO) and neurovascular disease.

Authors:  Mingming Ning; Eng H Lo; Pei-Chen Ning; Su-Yu Xu; David McMullin; Zareh Demirjian; Ignacio Inglessis; G William Dec; Igor Palacios; Ferdinando S Buonanno
Journal:  Pharmacol Ther       Date:  2013-03-23       Impact factor: 12.310

Review 9.  Pharmaco-proteomics opportunities for individualizing neurovascular treatment.

Authors:  M M Ning; M Lopez; D Sarracino; J Cao; M Karchin; D McMullin; X Wang; F S Buonanno; E H Lo
Journal:  Neurol Res       Date:  2013-06       Impact factor: 2.448

Review 10.  Patent foramen ovale and stroke: what should be done?

Authors:  Marco R Di Tullio; Shunichi Homma
Journal:  Curr Opin Hematol       Date:  2009-09       Impact factor: 3.284

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.